BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12440819)

  • 41. Increased Stromal Infiltrating Lymphocytes Are Associated with the Risk of Disease Progression in Mesenchymal Circulating Tumor Cell-Positive Primary Breast Cancer Patients.
    Smolkova B; Cierna Z; Kalavska K; Miklikova S; Plava J; Minarik G; Sedlackova T; Cholujova D; Gronesova P; Cihova M; Majerova K; Karaba M; Benca J; Pindak D; Mardiak J; Mego M
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33322711
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Medullary carcinoma of the breast: interobserver variability in histopathologic diagnosis.
    Gaffey MJ; Mills SE; Frierson HF; Zarbo RJ; Boyd JC; Simpson JF; Weiss LM
    Mod Pathol; 1995 Jan; 8(1):31-8. PubMed ID: 7731939
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunohistochemical analysis of tumor-infiltrating lymphocytes in breast carcinoma: relation to prognostic variables.
    Helal TE; Ibrahim EA; Alloub AI
    Indian J Pathol Microbiol; 2013; 56(2):89-93. PubMed ID: 24056641
    [TBL] [Abstract][Full Text] [Related]  

  • 44. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.
    Rosen PP; Lesser ML; Arroyo CD; Cranor M; Borgen P; Norton L
    J Clin Oncol; 1995 Apr; 13(4):821-30. PubMed ID: 7707107
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunohistochemical expression of alpha-smooth muscle actin in infiltrating ductal carcinoma of the breast with productive fibrosis.
    Tamiolakis D; Papadopoulos N; Cheva A; Lambropoulou M; Kotini A; Jivannakis T; Simopoulos C
    Eur J Gynaecol Oncol; 2002; 23(5):469-71. PubMed ID: 12440829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance.
    Althobiti M; Aleskandarany MA; Joseph C; Toss M; Mongan N; Diez-Rodriguez M; Nolan CC; Ashankyty I; Ellis IO; Green AR; Rakha EA
    Histopathology; 2018 Dec; 73(6):887-896. PubMed ID: 29947077
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlation of tumor-infiltrative lymphocyte subtypes alteration with neoangiogenesis before and after neoadjuvant chemotherapy treatment in breast cancer patients.
    Chan MS; Chen SF; Felizola SJ; Wang L; Nemoto N; Tamaki K; Ishida T; Chow LW; Ohuchi N; Sasano H
    Int J Biol Markers; 2014 Sep; 29(3):e193-203. PubMed ID: 24803281
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis.
    Ziai J; Gilbert HN; Foreman O; Eastham-Anderson J; Chu F; Huseni M; Kim JM
    PLoS One; 2018; 13(1):e0190158. PubMed ID: 29320521
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Immunophenotype of Nodular Variant of Medullary Carcinoma of the Breast.
    Reyes C; Nadji M
    Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):624-7. PubMed ID: 25710588
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is the tumor infiltrating natural killer cell (NK-TILs) count in infiltrating ductal carcinoma of breast prognostically significant?
    Rathore AS; Goel MM; Makker A; Kumar S; Srivastava AN
    Asian Pac J Cancer Prev; 2014; 15(8):3757-61. PubMed ID: 24870789
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical significance of tumor-infiltrating lymphocytes in neoplastic progression and lymph node metastasis of human breast cancer.
    Sheu BC; Kuo WH; Chen RJ; Huang SC; Chang KJ; Chow SN
    Breast; 2008 Dec; 17(6):604-10. PubMed ID: 18656354
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Medullary carcinoma of the breast. Prevalence and prognostic importance of classical risk factors in breast cancer.
    Pedersen L; Zedeler K; Holck S; Schiødt T; Mouridsen HT
    Eur J Cancer; 1995 Dec; 31A(13-14):2289-95. PubMed ID: 8652258
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for an antigen-driven antibody response elicited by tumor-infiltrating B cells.
    Hansen MH; Nielsen HV; Ditzel HJ
    J Immunol; 2002 Sep; 169(5):2701-11. PubMed ID: 12193744
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential regulation and function of tumor-infiltrating T cells in different stages of breast cancer patients.
    Zhu S; Lin J; Qiao G; Xu Y; Zou H
    Tumour Biol; 2015 Sep; 36(10):7907-13. PubMed ID: 25953262
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor-infiltrating lymphocytes predict prognosis of breast cancer patients treated with anti-Her-2 therapy.
    Chen TH; Zhang YC; Tan YT; An X; Xue C; Deng YF; Yang W; Yuan X; Shi YX
    Oncotarget; 2017 Jan; 8(3):5219-5232. PubMed ID: 28029650
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients--an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients.
    Chan MS; Wang L; Felizola SJ; Ueno T; Toi M; Loo W; Chow LW; Suzuki T; Sasano H
    Int J Biol Markers; 2012 Dec; 27(4):e295-304. PubMed ID: 23280127
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor-infiltrating lymphocytes are associated with β-catenin overexpression in breast cancer.
    Ma X; Zhao X; Yan W; Yang J; Zhao X; Zhang H; Hui Y; Zhang S
    Cancer Biomark; 2018 Feb; 21(3):639-650. PubMed ID: 29286921
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.
    Liyanage UK; Moore TT; Joo HG; Tanaka Y; Herrmann V; Doherty G; Drebin JA; Strasberg SM; Eberlein TJ; Goedegebuure PS; Linehan DC
    J Immunol; 2002 Sep; 169(5):2756-61. PubMed ID: 12193750
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.
    Nielsen JS; Sahota RA; Milne K; Kost SE; Nesslinger NJ; Watson PH; Nelson BH
    Clin Cancer Res; 2012 Jun; 18(12):3281-92. PubMed ID: 22553348
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma.
    Jacquemier J; Bertucci F; Finetti P; Esterni B; Charafe-Jauffret E; Thibult ML; Houvenaeghel G; Van den Eynde B; Birnbaum D; Olive D; Xerri L
    Int J Cancer; 2012 Jan; 130(1):96-104. PubMed ID: 21328335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.